Φορτώνει......
The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
BACKGROUND: Hypomethylating agents (HMAs), such as decitabine (DAC), are currently used as first-line therapy for patients with high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) not eligible for standard chemotherapies. Exacerbation of thrombocytopenia is one of the prev...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Manag Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735651/ https://ncbi.nlm.nih.gov/pubmed/31564981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213931 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|